GO:0043490 malate-aspartate shuttle: Metabolic Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043490 (malate-aspartate shuttle) is the biological process that transfers reducing equivalents from cytosolic NADH into mitochondria via malate and aspartate.
• The shuttle is a closed cycle of four enzymatic reactions and two mitochondrial carriers: cytosolic and mitochondrial aspartate aminotransferases (GOT1, GOT2), cytosolic and mitochondrial malate dehydrogenases (MDH1, MDH2), the malate-alpha-ketoglutarate carrier (SLC25A11), and the glutamate-aspartate carrier (SLC25A12/SLC25A13).
• Inborn errors of the malate-aspartate shuttle cause severe neurological and metabolic disease, including developmental delay, epilepsy, and hyperammonemia.
• The shuttle is essential for de novo serine biosynthesis, thermogenic lipid mobilization in brown adipocytes, and mitochondrial lactate oxidation.
• Aspartate availability is a key determinant of differential malate-aspartate shuttle engagement across cell types and conditions.
• CRISPR knockout, point-mutation, knock-in, and overexpression models of shuttle genes enable causal dissection of its roles in cancer, metabolism, and neurodevelopment.
Description
The malate-aspartate shuttle (GO:0043490) is a conserved metabolic cycle that transfers reducing equivalents from NADH generated in the cytosol into the mitochondrial matrix, where they can be used by the electron transport chain. Because the inner mitochondrial membrane is impermeable to NADH, the shuttle uses malate and aspartate as carriers of reducing power and amino groups, respectively. This process is essential for maintaining cytosolic NAD+/NADH balance and for sustaining mitochondrial oxidative phosphorylation in many tissues. The shuttle was first described by Borst and colleagues and has since been recognized as a major metabolic pathway with broad physiological and pathological relevance. Research on the malate-aspartate shuttle has expanded from classical biochemistry to human genetics, cancer metabolism, and immunometabolism. Mutations in shuttle components cause inborn errors of metabolism with severe neurological phenotypes, and the shuttle is increasingly implicated in tumor progression and metabolic reprogramming. Understanding its molecular components, regulation, and disease connections is therefore critical for both basic and translational research. This article provides a research-grade overview of GO:0043490, covering its definition, core mechanism, key genes, disease associations, and experimental models. It is intended for researchers seeking to study the malate-aspartate shuttle using CRISPR-based approaches and other functional genomics methods.
malate-aspartate shuttle At A Glance
| GO ID | GO:0043490 |
|---|---|
| GO term | malate-aspartate shuttle |
| Ontology | biological_process |
| Synonym | malate aspartate shuttle; malate/aspartate shuttle; malate:aspartate shuttle |
| Major function | Transfer of reducing equivalents from cytosolic NADH to mitochondria via malate and aspartate |
| Key enzymes | GOT1, GOT2, MDH1, MDH2 |
| Key carriers | SLC25A11 (malate-alpha-ketoglutarate carrier), SLC25A12/SLC25A13 (glutamate-aspartate carrier) |
| Subcellular location | Cytosol and mitochondrial matrix/inner membrane |
| Pathological relevance | Inborn errors of metabolism, cancer, neurological disorders |
What Is GO:0043490?
The malate-aspartate shuttle is a biological process that transfers reducing equivalents from cytosolic NADH to the mitochondrial matrix via malate. In the cytosol, aspartate aminotransferase (GOT1) converts aspartate to oxaloacetate, and malate dehydrogenase (MDH1) uses NADH to convert oxaloacetate to malate. The malate-alpha-ketoglutarate carrier (SLC25A11) then transports malate into the mitochondria, where mitochondrial malate dehydrogenase (MDH2) uses NAD+ to convert malate back to oxaloacetate, generating mitochondrial NADH that can feed the electron transport chain. Mitochondrial aspartate aminotransferase (GOT2) converts oxaloacetate to aspartate, and the glutamate-aspartate carrier (SLC25A12/SLC25A13) transports aspartate back to the cytosol to complete the cycle.
Why Is malate-aspartate shuttle Important in Cell Biology?
The malate-aspartate shuttle is essential for maintaining cellular redox balance and energy metabolism. It enables the transfer of reducing equivalents from cytosolic NADH into mitochondria, supporting oxidative phosphorylation and biosynthetic pathways such as de novo serine biosynthesis. Defects in shuttle components cause severe inborn errors of metabolism with neurological and systemic manifestations. The shuttle is also implicated in cancer progression, thermogenesis, and lactate oxidation, making it a target of interest for metabolic research and therapeutic development.
• Maintains cytosolic NAD+/NADH ratio and supports glycolysis.
• Enables mitochondrial oxidation of cytosolic NADH for ATP production.
• Required for de novo serine biosynthesis.
• Supports thermogenic lipid mobilization in brown adipocytes.
• Promotes mitochondrial lactate oxidation.
• Aspartate availability regulates differential shuttle engagement.
• Mutations cause inborn errors of the malate-aspartate shuttle with severe neurological phenotypes.
• Implicated in cancer progression via c-Myc and LMNA-related pathways.
• Provides a model system for studying mitochondrial carriers and redox shuttles.
• Offers targets for metabolic engineering and therapeutic intervention.
What Happens During malate-aspartate shuttle?
Cytosolic transamination and reduction
In simple terms: In the cytosol, aspartate is converted to oxaloacetate, which is then turned into malate using NADH.
Cytosolic aspartate aminotransferase (GOT1) catalyzes the conversion of aspartate to oxaloacetate, transferring an amino group to alpha-ketoglutarate to form glutamate. Cytosolic malate dehydrogenase (MDH1) then uses NADH to reduce oxaloacetate to malate, oxidizing NADH to NAD+. This step is critical for regenerating cytosolic NAD+ and capturing reducing equivalents in malate.
Mitochondrial transport of malate
In simple terms: Malate is carried into the mitochondria by a specific carrier protein.
The malate-alpha-ketoglutarate carrier (SLC25A11) exchanges cytosolic malate for mitochondrial alpha-ketoglutarate across the inner mitochondrial membrane. This transport step is essential for delivering reducing equivalents into the mitochondrial matrix.
Mitochondrial oxidation and transamination
In simple terms: Inside mitochondria, malate is converted back to oxaloacetate, producing NADH, and then to aspartate.
Mitochondrial malate dehydrogenase (MDH2) uses NAD+ to oxidize malate to oxaloacetate, generating mitochondrial NADH that can be used by the electron transport chain. Mitochondrial aspartate aminotransferase (GOT2) then converts oxaloacetate to aspartate, transferring an amino group from glutamate.
Aspartate export and cycle completion
In simple terms: Aspartate is transported back to the cytosol to complete the cycle.
The glutamate-aspartate carrier (SLC25A12/SLC25A13) transports mitochondrial aspartate to the cytosol in exchange for glutamate. This completes the cycle, allowing continuous transfer of reducing equivalents from cytosolic NADH to mitochondria.
Regulation by aspartate availability
In simple terms: The shuttle's activity depends on how much aspartate is available in the cell.
Aspartate availability drives differential engagement of the malate-aspartate shuttle, influencing metabolic flux and cellular redox state. This regulation is important for adapting to changes in nutrient supply and metabolic demand.
Key Genes Involved in GO:0043490 malate-aspartate shuttle
The malate-aspartate shuttle involves a set of enzymes and mitochondrial carriers that work together to transfer reducing equivalents.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GOT1 | Cytosolic aspartate aminotransferase; converts aspartate to oxaloacetate | Redox balance, cancer metabolism, serine biosynthesis |
| GOT2 | Mitochondrial aspartate aminotransferase; converts oxaloacetate to aspartate | Mitochondrial metabolism, inborn errors |
| MDH1 | Cytosolic malate dehydrogenase; reduces oxaloacetate to malate using NADH | Cytosolic NAD+ regeneration, glycolysis |
| MDH2 | Mitochondrial malate dehydrogenase; oxidizes malate to oxaloacetate using NAD+ | Mitochondrial NADH production, TCA cycle |
| SLC25A11 | Malate-alpha-ketoglutarate carrier; transports malate into mitochondria | Mitochondrial transport, inborn errors |
| SLC25A12 | Glutamate-aspartate carrier (aralar); transports aspartate out of mitochondria | Neurodevelopment, inborn errors |
| SLC25A13 | Glutamate-aspartate carrier (citrin); transports aspartate out of mitochondria | Citrin deficiency, hyperammonemia |
| GOT1L1 | Aspartate aminotransferase-like; potential role in shuttle | Testis-specific metabolism |
| MDH1B | Malate dehydrogenase 1B; potential cytosolic isoform | Metabolic regulation |
| MDH2P1 | Malate dehydrogenase 2 pseudogene | Genomic regulation |
| SLC25A11P1 | SLC25A11 pseudogene | Genomic regulation |
| GOT2P1 | GOT2 pseudogene | Genomic regulation |
| GOT1P1 | GOT1 pseudogene | Genomic regulation |
| MDH1P1 | MDH1 pseudogene | Genomic regulation |
| SLC25A12P1 | SLC25A12 pseudogene | Genomic regulation |
| SLC25A13P1 | SLC25A13 pseudogene | Genomic regulation |
| MYC | Regulates tRNA processing and malate-aspartate shuttle genes | Cancer progression |
| LMNA | Modulates c-Myc transactivation and shuttle gene expression | Cancer, laminopathies |
How Is malate-aspartate shuttle Regulated?
The malate-aspartate shuttle is regulated at multiple levels. Aspartate availability directly influences shuttle engagement, with differential utilization depending on cellular metabolic state. The transcription factor c-Myc, modulated by LMNA, regulates tRNA processing and expression of malate-aspartate shuttle components, linking the shuttle to tumor progression. Inborn errors of the shuttle also reveal that loss of individual components can lead to compensatory changes in related metabolic pathways.
malate-aspartate shuttle and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC25A12 | Inborn error of metabolism with neurological symptoms | Knockout and point-mutation cell models |
| SLC25A13 | Citrin deficiency, hyperammonemia | Knockout and knock-in models |
| GOT1 | Cancer metabolism, redox imbalance | Overexpression and knockout models |
| GOT2 | Inborn error of metabolism, cancer | Point-mutation and knockout models |
| MDH2 | Inborn error of metabolism, cancer | Knockout and overexpression models |
Inborn errors of the malate-aspartate shuttle
Mutations in genes encoding shuttle components, such as SLC25A12, SLC25A13, GOT1, GOT2, MDH1, and MDH2, cause inborn errors of metabolism with severe neurological phenotypes, including developmental delay, epilepsy, and hyperammonemia. These disorders highlight the critical role of the shuttle in brain metabolism and ammonia detoxification.
Cancer metabolism
The malate-aspartate shuttle is upregulated in several cancers and supports tumor progression by maintaining redox balance and supplying biosynthetic precursors. Targeting c-Myc transactivation by LMNA inhibits tRNA processing essential for malate-aspartate shuttle function, suggesting therapeutic potential.
Metabolic and thermogenic disorders
The shuttle supports thermogenic lipid mobilization in brown adipocytes, and its dysfunction may contribute to obesity and metabolic disorders. It also promotes mitochondrial lactate oxidation, linking it to lactate utilization and metabolic flexibility.
Serine biosynthesis defects
The malate-aspartate shuttle is important for de novo serine biosynthesis, and its impairment can affect nucleotide and amino acid metabolism. This connection has implications for cancer and developmental disorders.
From malate-aspartate shuttle-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GOT1 affect cytosolic NAD+/NADH ratio? | GOT1 knockout cell line |
| Does a specific point mutation in SLC25A11 impair malate transport? | SLC25A11 point-mutation knock-in |
| Can overexpression of MDH2 rescue mitochondrial NADH production? | MDH2 overexpression cell line |
| Does tagging endogenous GOT2 affect its mitochondrial localization? | GOT2 tagged knock-in |
| Does knockout of SLC25A12 alter aspartate export? | SLC25A12 knockout cell line |
| Can CRISPR library screening identify synthetic lethal partners of shuttle genes? | Genome-wide CRISPR knockout library screening |
How to Study the malate-aspartate shuttle Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Gene expression levels | Transcriptional regulation of shuttle genes |
| Ribo-seq | Translation efficiency | Translational control of shuttle components |
| Proteomics | Protein abundance | Quantification of shuttle enzymes |
| Metabolomics | Metabolite levels | Measurement of malate, aspartate, NADH/NAD+ |
| Isotope tracing | Metabolic flux | Shuttle activity in live cells |
| Live-cell imaging | NADH/NAD+ dynamics | Real-time shuttle function |
| CRISPR library screening | Gene essentiality and interactions | Identification of synthetic lethal partners |
Genomic and transcriptomic profiling
RNA-seq and Ribo-seq can measure expression and translation of malate-aspartate shuttle genes under different metabolic conditions. These methods help identify transcriptional and translational regulation of shuttle components.
Proteomics and metabolomics
Proteomics can quantify protein levels of shuttle enzymes and carriers, while metabolomics can measure malate, aspartate, oxaloacetate, and NADH/NAD+ ratios to assess shuttle activity.
Imaging and flux analysis
Live-cell imaging with genetically encoded NADH sensors and isotope tracing can monitor shuttle flux in real time. These approaches are useful for studying thermogenic adipocytes and cancer cells.
CRISPR-based functional genomics
CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of shuttle gene function in disease-relevant cell types. Library screening can identify genetic interactions and synthetic lethal partners.
How CRISPR Can Be Used to Study GO:0043490 malate-aspartate shuttle
Knockout
CRISPR knockout of shuttle genes such as GOT1, GOT2, MDH1, MDH2, SLC25A11, SLC25A12, and SLC25A13 allows researchers to study loss-of-function phenotypes, including changes in redox balance, proliferation, and metabolism.
Point Mutation
Point-mutation knock-in models can recapitulate patient-specific mutations in shuttle genes, enabling studies of disease mechanisms and genotype-phenotype correlations.
Knock-in
Tagged knock-in of shuttle enzymes (e.g., GFP or HA tags) facilitates localization, interaction, and dynamic studies using imaging and proteomics.
Overexpression
Overexpression of shuttle components can rescue loss-of-function phenotypes or enhance metabolic flux, providing insights into rate-limiting steps and therapeutic potential.
How EDITGENE Supports malate-aspartate shuttle Research
Researchers studying malate-aspartate shuttle-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation, disease progression, or therapeutic response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for malate-aspartate shuttle research.
Frequently Asked Questions About malate-aspartate shuttle
What is the malate-aspartate shuttle?
The malate-aspartate shuttle (GO:0043490) is a biological process that transfers reducing equivalents from cytosolic NADH into mitochondria via malate and aspartate.
What genes are involved in the malate-aspartate shuttle?
Key genes include GOT1, GOT2, MDH1, MDH2, SLC25A11, SLC25A12, and SLC25A13.
What diseases are associated with malate-aspartate shuttle defects?
Inborn errors of the shuttle cause neurological and metabolic disorders, and the shuttle is implicated in cancer and thermogenic disorders.
How is the malate-aspartate shuttle regulated?
It is regulated by aspartate availability and transcriptional control via c-Myc and LMNA.
Why is the malate-aspartate shuttle important for cancer?
It supports redox balance and biosynthetic pathways in cancer cells, and its inhibition can impair tumor progression.
What is the role of SLC25A11 in the shuttle?
SLC25A11 is the malate-alpha-ketoglutarate carrier that transports malate into mitochondria.
How can CRISPR be used to study the malate-aspartate shuttle?
CRISPR knockout, point-mutation, knock-in, and overexpression models enable functional studies of shuttle genes.
What is the connection between the malate-aspartate shuttle and serine biosynthesis?
The shuttle is important for de novo serine biosynthesis, linking it to amino acid metabolism.
Does the malate-aspartate shuttle play a role in thermogenesis?
Yes, it supports thermogenic lipid mobilization in brown adipocytes.
What methods are used to study the malate-aspartate shuttle?
Methods include RNA-seq, Ribo-seq, proteomics, metabolomics, isotope tracing, and live-cell imaging.
Conclusion
The malate-aspartate shuttle (GO:0043490) is a fundamental metabolic pathway that couples cytosolic and mitochondrial redox metabolism. Its components are implicated in severe inborn errors of metabolism, cancer, and metabolic disorders, making it a compelling target for research. Advances in CRISPR-based models and functional genomics provide powerful tools to dissect its regulation and therapeutic potential. EDITGENE offers a comprehensive suite of CRISPR services to support mechanistic and translational studies of the malate-aspartate shuttle, from knockout and point-mutation models to library screening and bioinformatics.
References
- 1. Borst P. 2020. The malate-aspartate shuttle (Borst cycle): How it started and developed into a major metabolic pathway.. IUBMB Life 72(11):2241-2259 PMID: 32916028
- 2. Broeks MH et al.. 2021. Inborn disorders of the malate aspartate shuttle.. J Inherit Metab Dis 44(4):792-808 PMID: 33990986
- 3. Koch J et al.. 2024. Inborn errors of the malate aspartate shuttle - Update on patients and cellular models.. Mol Genet Metab 142(4):108520 PMID: 38945121
- 4. Veliova M et al.. 2025. The Malate-Aspartate Shuttle supports thermogenic lipid mobilization in brown adipocytes.. bioRxiv PMID: 40799572
- 5. Altinok O et al.. 2020. Malate-aspartate shuttle promotes l-lactate oxidation in mitochondria.. J Cell Physiol 235(3):2569-2581 PMID: 31490559
- 6. Broeks MH et al.. 2023. The malate-aspartate shuttle is important for de novo serine biosynthesis.. Cell Rep 42(9):113043 PMID: 37647199
- 7. Brunner JS et al.. 2026. Aspartate availability drives differential engagement of the malate-aspartate shuttle.. Mol Cell 86(5):954-967.e7 PMID: 41759528
- 8. Wang J et al.. 2024. Targeting c-Myc transactivation by LMNA inhibits tRNA processing essential for malate-aspartate shuttle and tumour progression.. Clin Transl Med 14(5):e1680 PMID: 38769668
